Study of CP-675,206 in Refractory Melanoma
Public ClinicalTrials.gov record NCT00254579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.
Study identification
- NCT ID
- NCT00254579
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 251 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2005 (Type not available)
- Primary completion
- Dec 2009 (Actual)
- Completion
- Dec 2009 (Actual)
- Last update posted
- Jun 7, 2012
2005 – 2009
United States locations
- U.S. sites
- 36
- U.S. states
- 20
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85260 | — |
| Research Site | Bentonville | Arkansas | 72712 | — |
| Research Site | Fayetteville | Arkansas | 72703 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Los Angeles | California | 90095-6970 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Stamford | Connecticut | 06902-3628 | — |
| Research Site | Ocoee | Florida | 34761 | — |
| Research Site | Orlando | Florida | 32803 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Indianapolis | Indiana | 46237 | — |
| Research Site | Indianapolis | Indiana | 46260 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Baltimore | Maryland | 21237-3998 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Ann Arbor | Michigan | 48109-0946 | — |
| Research Site | Buffalo | New York | 14263 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Chapel Hill | North Carolina | 27599-7600 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Columbus | Ohio | 43210 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Bethlehem | Pennsylvania | 18015 | — |
| Research Site | Pittsburgh | Pennsylvania | 15232 | — |
| Research Site | Nashville | Tennessee | 37232-6307 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
| Research Site | Federal Way | Washington | 98003 | — |
| Research Site | Lakewood | Washington | 98499 | — |
| Research Site | Seattle | Washington | 98104 | — |
| Research Site | Seattle | Washington | 98122 | — |
| Research Site | Tacoma | Washington | 98405 | — |
| Research Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00254579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2012 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00254579 live on ClinicalTrials.gov.